阿尼卡疗法 ANIK 深 沪
已收盘 02-06 16:00:00 美东时间
10.46
+0.160
+1.55%
华盛通- 最 高10.54
- 今 开10.40
- 成交量 13.95万股
- 最 低 10.20
- 昨 收 10.30
- 总市值 1.51亿
- 52周最高 18.345
- 市盈率 静 --
- 换手率 0.97%
- 52周最低 7.8701
- 委 比 -39.13%
- 总股本 1442.12万
- 历史最高 75.715
- 量 比 0.55
- 振 幅 3.30%
- 历史最低 5.24
- 每 手 1
- 风险率 2.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $16 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $16 price target.
01-09 21:00
CFO And COO Steve Griffin to Take Over as Anika CEO While Cheryl Blanchard Becomes Executive Chair
Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that Stephen (Steve)
01-08 20:10
Anika Therapeutics Announces Leadership Transition
Anika Therapeutics announced that Stephen (Steve) Griffin, current CFO and COO, has been appointed President and CEO, effective February 1, 2026, succeeding Cheryl Blanchard, who will become Executive Chair of the Board. Griffin, with a track record of strategic transformation and operational excellence, will focus on accelerating growth, improving profitability, and delivering value to patients and shareholders.为确保总结不超过400字符，进一步精简： Anika Therap...
01-08 12:00
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
2025-11-07 10:14
Anika Therapeutics Q3 Adj. EPS $0.04 Beats $(0.27) Estimate, Sales $27.800M Inline
Anika Therapeutics (NASDAQ:ANIK) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $(0.27) by 114.81 percent. This is a 116 percent increase over losses of $(0.25) per share from
2025-11-05 20:17
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study
Anika Therapeutics submitted the final module of its Hyalofast PMA to the FDA on October 31, 2025. The PMA includes 24-month FastTRACK Phase III clinical trial data and additional analyses. While the trial did not meet its pre-specified co-primary endpoints, Hyalofast demonstrated statistically significant improvements in key secondary endpoints, including KOOS Sports and Recreation, Quality of Life, and Total KOOS. Post-hoc analyses also showed ...
2025-11-05 12:00
美股大行评级 | 升至450美元，瑞穗上调特斯拉目标价；富国银行上调CoreWeave至"超配"，目标价升至170美元
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从44美元升至84美元；Oppenheimer：维持MBX Biosciences"跑赢大市"评级，目标价从38美元升至80美元
2025-09-24 10:23
Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $15 Price Target
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 price target.
2025-09-23 23:01
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) stock rose 100.5% to $7.52 during Wednes...
2025-07-31 01:07
